Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses
Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to detect pancreatic cancer at an earlier stage, to improve current method of T staging and assessment of surgical resectability and also to distinguish between benign and malignant pancreatic masses. All these will translate into better clinical outcome, and also avoid unnecessary surgery in situations of unresectable cancers.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01703026
|Changi General Hospital|